Effect of tetrandrine combined with epirubicin on the growth of human breast carcinoma multidrug resistance cell line

Yakugaku Zasshi

Volumn 128, Issue 4, 2008, Pages 663-666

  Hou, Yue ^a,b   Guo, Tao ^b   Wu, Chunfu ^a   He, Xiang ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Epirubicin; Multidrug resistance; Tetrandrine

Indexed keywords

EPIRUBICIN; TETRANDRINE;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZYLISOQUINOLINES; BREAST NEOPLASMS; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EPIRUBICIN; FEMALE; G2 PHASE; HUMANS;

EID: 41849102706     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.663     Document Type: Article

References (13)

1. Ling V., Cancer Chemother. Pharmacol., 40 (Suppl.), S3-10 (1997).
2. Szabo D., Keyzer H., Kaiser H. E., Molnar J., Anticancer Res., 20, 4261-4274 (2000).
3. Motoji T., Motomura S., Wang Y. H., Int. J. Hematol., 72, 418-424 (2000).
4. van den Heuvel-Eibrink M. M., Sonneveld P., Pieters R., Int. J. Clin. Pharmacol. Ther., 38, 94-110 (2000).
5. Scheper R. J., Broxterman H. J., Scheer G. L., Kaaijk P., Dalton W. S., van Heijningen T. H., van Kalken C. K., Slovak M. L., de Vries E. G., van der Valk P., Cancer Res., 53, 1475-1479 (1993).
6. Volm M., Anticancer Res., 18, 2905-2917 (1998).
7. Malayeri R., Filipits M., Suchomel R. W., Zochbauer S., Lechner K., Pirker R. Leuk. Lymphoma., 23, 451-458 (1996).
8. Krishna R., Mayer L. D., Eur. J. Pharm. Sci., 11, 265-283 (2000).
9. Sikic B. I., Fisher G. A., Lum B. L., Halsey J., Beketic-Oreskovic L., Chen G., Cancer Chemother. Pharmacol., 40 (Suppl.), S13-19 (1997).
10. Liu Z. L., Hirano T., Tanaka S., Onda K., Oka K., J. Pharm. Pharmacol., 55, 1531-1537 (2003).
11. Fu L., Liang Y., Deng L., Ding Y., Chen L., Ye Y., Yang X., Pan Q., Cancer Chemother. Pharmacol., 53, 349-356 (2004).
12. Fu L. W., Zhang Y. M., Liang Y. J., Yang X. P., Pan Q. C., Eur. J. Cancer, 38, 418-426 (2002).
13. Hou Y., Guo T., Wu C. F., He X., Zhao M. H., Yakugaku Zasshi, 126, 1383-1386 (2006).